Key result
Activated bypassing agents successfully controlled bleeding in a patient who developed an acquired factor V inhibitor during dabigatran therapy for chronic atrial fibrillation.
Why the study?
Acquired factor V inhibitor is a rare condition described only in case reports, where the role of activated bypassing agents in bleeding control needed evaluation.
Activated bypassing agents can successfully treat bleeding in rare cases of acquired factor V inhibitor associated with dabigatran use.
May support activated bypassing agents for bleeding in acquired factor V inhibitor; hypothesis-generating at Level 5 evidence, warranting prospective trials.
Acquired factor V inhibitor represents a rare condition, described only in case reports. The use of activated bypassing agents in bleeding control could be of aid and improve the survival in symptomatic patients with acquired factor V inhibitor.
No takes yet. Share an insight, caveat, or question.
Giuffrida et al. (2020) studied this question. Activated bypassing agents successfully controlled bleeding in a patient who developed an acquired factor V inhibitor during dabigatran therapy for chronic atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: